LyondellBasell Sells the Refinery — and Quietly Moves Its Recycling Bet to Europe

A record oxyfuels quarter and $1.4B of free cash flow made the headline; a $320.5M site sale and a relocated MoReTec-2 changed the company underneath it.

LYB · Earnings Call · 2026-10-30

The refinery found a buyer — and MoReTec-2 lost its address

LyondellBasell's third quarter was, on the numbers, a strong one: $1.5 billion of EBITDA, an 18% EBITDA margin, $1.4 billion of free cash flow, and a cash balance up roughly $600 million to $3.2 billion even after repaying a EUR 500 million note. Yet the item that actually changes the company's shape sits in the prepared remarks: an agreement to sell the shuttered Houston refinery site and associated assets to Valero for $320.5 million in cash, expected to close by end-2026, with the buyer assuming site operations, environmental liabilities and pension costs. Management frames the benefit as $50 million to $100 million of annual cash flow improvement and, in the CEO's words, “a real estate and a capital allocation decision rather than a change in our corporate strategy.” — Peter Z. Vanacker, Chief Executive Officer · 2026-10-30 That clause deserves scrutiny. As recently as the January call, asked whether the site might be monetised, Vanacker said “our plan continues to be, as we have explained... we continue to remain very open in what we can do, I mean with the existing assets that we have there.” — Peter Z. Vanacker, Chief Executive Officer · 2026-01-30 The most obvious "thing we can do" turned out to be the site's original purpose — sell it to a refiner. But that site was also the designated home of the company's second chemical-recycling plant, which in August 2025 was described as “planned to be built in our sites, the refinery site in Houston... a capacity of 100,000 tonnes.” — Peter Z. E. Vanacker, Chief Executive Officer · 2025-08-01 On Friday:

In the U.S., we do not yet see strong regulatory support that would eventually enable an investment in MoReTec-2. So as a result... we're assuming that MoReTec-2 would also be in Europe and any MoReTec deployment in the United States would be aligned, I mean, to demand visibility and also progress on regulation.
Peter Z. Vanacker, Chief Executive Officer · 2026-10-30

So MoReTec 2 — the company's highest-momentum keyword this quarter — has not merely been deferred, it has been re-homed. MoReTec 1 at Wesseling, start-up expected toward the end of 2027, is now the entire visible circularity pipeline. The refinery exit is a clean portfolio decision; the recycling pivot it forces is a strategy change whether or not it carries that label.

Record oxyfuels, and the squeeze already underway

The quarter's engine was Intermediates & Derivatives, where EBITDA more than doubled sequentially to a record $795 million on what Aaron Ledet called tighter gasoline supply driving octane values higher and improving gasoline pool economics. O&P Americas earned $641 million at a 20% margin; O&P Europe/Asia/International just $13 million; APS $45 million; Technology $29 million. tight supply in fuels offset a weaker polymer quarter — precisely the argument for the diversified portfolio the CEO spends most of his prepared remarks defending, noting building and construction is only about 5% of end-market exposure. The October read-through is less kind: “margins were at record levels coming out of September, and we have seen a steady decline throughout October... If you look at butane as a percentage of crude, it's almost 70% in the U.S. and close to 90% in Europe.” — Aaron Ledet, Senior Vice President, Intermediates & Derivatives · 2026-10-30 That butane price mechanism is now broadening into the whole feedstock slate: “Today, ethane is sitting at about $0.30 a gallon, which is 24% higher than the third quarter average.” — Kimberly Foley, Executive Vice President, Olefins & Polyolefins Americas · 2026-10-30 Hence fourth-quarter operating-rate guidance of roughly 85% in the Americas, 60% in Europe and 75% in I&D — a margin statement wearing a volume costume. feedstock costs and logistic constraints (low Rhine levels, expensive freight) are the two levers deciding whether this record quarter is a peak or a plateau, even as export demand stays unusually firm into November.

What management stopped saying

Two themes went quiet. Polypropylene, for several quarters the portfolio's sleeping giant, has dropped out of the company's top-30 keywords entirely, surviving only as a $0.03/lb November spread increase and a passing reference to polypropylene compounds in APS. Equally absent is the Chinese anti involution rationalization story that was the company's number-one keyword a year ago; the supply-side argument has been rehoused inside licensing. And that reframing is worth flagging — the collapse in new licence demand, presented for five straight quarters as a Technology segment headwind, now arrives with the opposite sign: “we continue to see increasingly weaker demand for new licenses over the past 3 years, which indicates a dramatic slowdown of new capacity additions by the end of the decade.” — Peter Z. Vanacker, Chief Executive Officer · 2026-10-30 Same fact, opposite valence. The third silence is the most telling. Through late 2025 and January 2026, analysts pressed on a double-digit dividend yield and a payout the company wasn't covering. That question is gone. The answer is now a flat restatement: “Investment grade, very important, making sure net leverage comes down, maintenance on our assets to run them safe and reliably, dividend growth and eventually buybacks to offset dilution.” — Agustin Izquierdo, Chief Financial Officer · 2026-10-30 A $900 million bond matures in Q1 2027 and is queued for repayment. Buybacks remain at zero.

The tape is already voting

The stock is up 22.9% over the last 90 trading days into this print — a re-rating off a deep multi-year drawdown rather than a breakout, with the shares still far below their 2018 peak. What the filed fundamentals show is that the trough genuinely broke: $9.2 billion of revenue in the June quarter, up 28% quarter over quarter, operating income of $1.5 billion and free cash flow of $463 million after a negative stretch. Leverage is healing too: net debt of $7.1 billion and interest coverage of 11.2x against a negative figure a year ago. Peer chatter corroborates the cost side: Olin, reporting in the same window, flagged steep increases in freight costs plus further structural cost reduction — the same two levers LYB is pulling. The bear case isn't the balance sheet, it's the calendar. “Any eventual normalization in markets is likely to take quarters, not months,” — Peter Z. Vanacker, Chief Executive Officer · 2026-10-30 a refrain now running across three straight calls — the July version was simply “normalization isn't a straight line.” — Peter Z. Vanacker, Chief Executive Officer · 2026-07-31 That cuts both ways: a longer disruption extends the oxyfuels windfall and deepens feedstock inflation and European logistics pain simultaneously. And the refinery sale plus the MoReTec-2 relocation reveal management's real posture: it is monetising the past and outsourcing the future to European regulators rather than betting capital on a return to normal. That is a defensible display of discipline capital allocation — and the reason a 12% yield stopped being a question — but it means the next leg of this story rests on octane spreads, not on a new plant.